Suven life sciences ltd.

Introduction
Suven Life Sciences Limited is a bio-pharmaceutical company. The Company is
engaged in the business of manufacture and sale of bulk drugs and
intermediaries. The Company is engaged in the drug discovery specializing in
central nervous system (CNS)-based programs with over four of the molecules
in pipeline under clinical phase of development
It is an Indian life sciences company based in Hyderabad, Telangana, India.
Established in 1989 as a private limited company, it went public in 1995. The
company designs, manufactures and supplies bulk actives, drug
intermediates and fine chemicals to domestic and international players in the
bio-pharmaceuticals industry.

The company’s key business units include:

 Contract Research and Manufacturing Services (CRAMS)

Develops and supplies cost-effective pharmaceutical and agro
chemical intermediates for New Chemical Entities (NCE's) to 22 global life
science and fine chemical companies.
 
 Drug Discovery Research Services (DDRS)
Offers DDRS to global pharma and biotech companies in physicochemical
properties, screening (receptors/enzymes), assay development, drug
metabolism and pharmacokinetics in rodents, non-rodents, brain
penetration, microdialysis, receptor occupancy, CNS pharmacology, safety
pharmacology, and in-vivo rodent toxicology, histopathology, clinical
pathology and bioanalysis. 
 
 Formulation Development Center
Supports drug discovery and product delivery through customized and
dedicated formulation development laboratories, technology laboratories,
process development laboratories, packaging development and testing
laboratories, analytical method development and validation laboratories,
microbiology testing laboratory, stability chambers and warehouse
facilities.
 Vision & Mission
 Providing world-class R&D solutions for Global Life Science
companies with efficiency in cost, quality and speed.
 Become a leading company focused on treatments for unmet medical
needs in Mental Health
 Health for patients and Value for partners
 In search of new CNS therapies

Business segments
 Contract Research And Manufacturing Services
1) Intermediates
2) Active Pharma Ingredients
 Drug Discovery & Development Support Services (DDDSS)
1) Synthetic and Medicinal Chemistry
2) Analytical Chemistry
3) In vitro Biology
4) ADME
5) Pharmacology
6) Toxicology
7) Bioanalysis
8) NCE Formulations
 Drug Discovery & Research/Clinical pipeline
1) SUVN-502
2) SUVN-G3031
3) SUVN-D4010
4) SUVN-911
5) SUVN-I6107
6) Clinical Pipeline
7) Research Pipeline
8) Patent Portfolio
9)research publications

 Formulation Development
1) Dossiers
 CSR Policy
 Environment
 Community
 Health
 Water & sanitation
 Education
 Providing a safe & healthy workplace
 Ethical behavior

The IMS Policy

Suven Life Sciences Limited also has a integrated management system which it
ensures quality, health & safety and environment as an integral part of their
business philosophy.

Financial Highlights
 
 Relationships with over 22 global pharmaceutical companies 
 Exports comprised approx. 92% (Rs 499.63 Cr/ USD 77.06 million) of
the total revenue in 2016-17
 In the last 5 years, the company’s:
o Sales revenues increased by 211%
o EBIDTA grew by 333%
o Net profit increased by 400%.
 425-member strong R&D Center recognized by Department of
Scientific & Industrial Research (DSIR), Govt. of India
 One of the few players in the world in high-value CNS research
 Key global customers include AstraZeneca, Perrigo, Boehringer
Ingelheim, Pfizer, Bristol-Myers, Lilly, Bayer, Merck, Johnson & Johnson,
GSK, Celgene, Abbott, DuPont, Sanofi Aventis, Novartis and Fujifilm
 Offices in Hyderabad, India and NJ, USA
The shares of Suven Life Sciences Ltd. are listed on Bombay Stock Exchange
(BSE), National Stock Exchange (NSE), and Hyderabad Stock Exchange
(HSE).